Follow-Up Study Demonstrates Long-Term Treatment Benefits for Patients With CLL

Othman Al-Sawaf, MD, hematologist-oncologist at the University Hospital Cologne, Cologne, Germany, and study physician at the German CLL Study Group, discusses his recent study and highlights why treatment with venetoclax-obinutuzumab resulted in maintained superior efficacy for patients with chronic lymphocytic leukemia. 

About the speaker:

Othman Al-Sawaf is a hematologist-oncologist at the University Hospital Cologne, Cologne, Germany, and study physician at the German CLL Study Group (GCLLSG). He studied medicine at Medical School of RWTH Aachen University in Aachen, Germany, and joined the Department I of Internal Medicine I of Professor Michael Hallek at the University Hospital of Cologne in 2016. His research focus lies on basic and clinical research on chronic lymphocytic leukaemia (CLL). He works as coordinating physician and principal investigator for national and international phase II and III trials. As the GCLLSG medical monitor, Dr Al-Sawaf is a key contributor to the CLL14 trial and has particular interest on genomic aberrations, minimal residual disease and quality of life of patients treated with novel agents.​​​​​​​